Becton, Dickinson And Company · NYSE:BDX
Becton, Dickinson And — Merger or Acquisition (July 2025)
12 slides from Becton, Dickinson And's merger presentation, Jul 14, 2025
Slide 1: Accelerating the New BD Strategy
Accelerating the New BD Strategy July 14, 2025 Exhibit 99.3
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements This communication includes “forward-looking statements” as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed transaction
Slide 3: Important Information and Where to Find It
ACCELERATING THE NEW BD STRATEGY JULY 14, 2025 This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or tran
Slide 4: Basis of Presentation and Non-GAAP Measures
ACCELERATING THE NEW BD STRATEGY JULY 14, 2025 In addition to the financial measures presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), this communication includes certain non-GAAP financial measures (collectively, the “Non-GAAP Measures”), such as adjusted EBI
Slide 5: Key investment highlights
New Scaled pure-play medical technology company with uniquely leading positions in large, attractive end-markets, track record of innovation, and strong long-term cash generation and earnings growth fueled by BD Excellence Disciplined and balanced capital allocation framework with emphasis on shareh
Slide 6: Unlocking meaningful value for shareholders
Unlocking meaningful value for shareholders Definitive agreement under which BD will combine its Biosciences and Diagnostic Solutions business with Waters to create a leading life science tools and diagnostics company Tax-efficient Reverse Morris Trust; BD shareholders will own ~39.2% of the new com
Slide 7: Transaction accelerates New BD strategy
Transaction accelerates New BD strategy Fiscal 2024 revenue of ~$17.8B1, with a $70B+ addressable market expected to grow at ~5%2 Uniquely leading positions in large and attractive end-markets with best-in-class consumables revenue profile of over 90% More focused investment to accelerate innovation
Slide 8: New BD leading positions in attractive end-markets
Medication Management Solutions $3.3B Revenue Please see Basis of Presentation on slide 4 and Appendix for non-GAAP reconciliations. (1) BD information presented is for FY24. Numbers may not tie due to rounding. Addressable markets based on internal BD estimates. Category growths represent normalize
Slide 9: Strengthening innovation in core categories and expanding into high-growth adjacencies
Strengthening innovation in core categories and expanding into high-growth adjacencies Note: Includes recently launched and select pipeline products. HemoSphere Alta™ Smart Recovery Monitor Parata Max® 2 Central Fill BD Alaris™ Infusion System Pyxis™ Pro Swan IQ™ and ForeSight IQ™ Smart Sensors BD E
Slide 10: Unlocking long-term shareholder value
Unlocking long-term shareholder value New Waters transaction creates a life science and diagnostics leader focused on high-volume testing with a leading financial profile Maximizes BD shareholder value through ownership of combined company including upside of transaction synergies and growth opportu
Slide 11: Appendix
Appendix ACCELERATING THE NEW BD STRATEGY JULY 14, 2025
Slide 12: Supplemental Revenue Reconciliations
Supplemental Revenue Reconciliations For the Twelve Months Ended September 30, (Unaudited; $ in millions) Reflects Advanced Patient Monitoring Revenue for the period October 1, 2023 through September 2, 2024, giving effect as if Advanced Patient Monitoring had been acquired from Edwards Lifesciences
Becton Dickinson & — Merger or Acquisition (July 2025) on 6ix